Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

By Vijay Kumar Malesu A major analysis reveals which GLP-1 drugs deliver the best results for glucose control, weight loss, and side effect profiles, offering new clarity for diabetes care decisions.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Healthcare professionals are calling for a fundamental shift in public perception around medically supervised weight loss ...

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy. In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist ...

However, the drug did not decrease the slowing down of their metabolic rate usually observed with weight loss. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, or GIP, and ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on Wegovy.